A Phase IIa Open Label, Randomized Clinical Trial to Study the Safety and Efficacy of Vintafolide and the Combination of Vintafolide and Paclitaxel Compared to Paclitaxel in Subjects with Advanced Triple Negative Breast Cancer Using Etarfolatide (EC20) Subject Selection

Trial Profile

A Phase IIa Open Label, Randomized Clinical Trial to Study the Safety and Efficacy of Vintafolide and the Combination of Vintafolide and Paclitaxel Compared to Paclitaxel in Subjects with Advanced Triple Negative Breast Cancer Using Etarfolatide (EC20) Subject Selection

Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 31 Dec 2014

At a glance

  • Drugs Vintafolide (Primary) ; Paclitaxel
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Sponsors Merck & Co; Merck Sharp & Dohme
  • Most Recent Events

    • 03 Jul 2014 Status changed from not yet recruiting to withdrawn prior to enrolment as reported by ClinicalTrials.gov record.
    • 16 Dec 2013 Planned initiation date changed from 1 Sep 2013 to 1 Apr 2014 as reported by ClinicalTrials.gov.
    • 16 Dec 2013 Planned End Date changed from 1 May 2016 to 1 Nov 2016 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top